Corestemchemon Inc

166480

Company Profile

  • Business description

    Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.

  • Contact

    Pangyo 255 beongil 24 I & C Building, 2nd Floor
    yeonggi-do, Bundang-gu
    Seongnam
    Seoul13486
    KOR

    T: +82 24973711

    http://www.corestemchemon.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    376

Stocks News & Analysis

stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,979.4022.00-0.24%
CAC 407,874.8924.460.31%
DAX 4024,465.87225.050.93%
Dow JONES (US)45,010.29507.851.14%
FTSE 1009,109.5048.010.53%
HKSE25,633.2995.220.37%
NASDAQ21,020.02127.330.61%
Nikkei 22541,826.34655.021.59%
NZX 50 Index12,805.1311.070.09%
S&P 5006,358.9149.290.78%
S&P/ASX 2008,709.4027.80-0.32%
SSE Composite Index3,605.7323.430.65%

Market Movers